Evidence map›Paper›PMID 31006041›Full record

ArticleBioprocess and biosystems engineering2019

Design of a synthetic miniR1 plasmid and its production by engineered Escherichia coli.

Alvaro R Lara, Daniela Velázquez, Inés Penella, Fabiola Islas, Claudia H González-De la Rosa, Juan-Carlos Sigala

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alvaro R LaraDepartamento de Procesos y Tecnología, Universidad Autónoma Metropolitana-Cuajimalpa, Vasco de Quiroga 4871, Santa Fe, 05348, Mexico City, Mexico. alara@correo.cua.uam.mx.ORCID http://orcid.org/0000-0003-3535-7619
Daniela VelázquezPosgrado en Ciencias Naturales e Ingeniería, Universidad Autónoma Metropolitana-Cuajimalpa, Vasco de Quiroga 4871, Santa Fe, 05348, Mexico City, Mexico.
Inés PenellaPosgrado en Ciencias Naturales e Ingeniería, Universidad Autónoma Metropolitana-Cuajimalpa, Vasco de Quiroga 4871, Santa Fe, 05348, Mexico City, Mexico.
Fabiola IslasPosgrado en Ciencias Naturales e Ingeniería, Universidad Autónoma Metropolitana-Cuajimalpa, Vasco de Quiroga 4871, Santa Fe, 05348, Mexico City, Mexico.
Claudia H González-De la RosaDepartamento de Procesos y Tecnología, Universidad Autónoma Metropolitana-Cuajimalpa, Vasco de Quiroga 4871, Santa Fe, 05348, Mexico City, Mexico.
Juan-Carlos SigalaDepartamento de Procesos y Tecnología, Universidad Autónoma Metropolitana-Cuajimalpa, Vasco de Quiroga 4871, Santa Fe, 05348, Mexico City, Mexico.
Universidad Autónoma Metropolitana · MX

Funding

Consejo Nacional de Ciencia y Tecnología CIBIOGEM 264460
6 · The paper itself

Abstract

A synthetic plasmid consisting of the minimal elements for replication control of the R1 replicon and kanamycin resistance marker, which was named pminiR1, was developed. pminiR1 production was tested at 30 °C under aerobic and microaerobic conditions in Escherichia coli W3110 recA

Indexed as

Escherichia coliMicroorganisms, Genetically-ModifiedPlasmidsBacterial ProteinsChromosomes, BacterialRecombinant ProteinsTruncated HemoglobinsBacterial Proteinshemoglobin protein, VitreoscillaRecombinant ProteinsTruncated HemoglobinsMicroaerobicMinimal plasmidR1 repliconSynthetic plasmidVitreoscilla hemoglobin

Identifiers

PMID31006041
OpenAlexW2935984126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.